GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports that, under its existing share buyback programme, it repurchased 498,759 ordinary shares (31¼p nominal) on 05 Aug 2025 through Merrill Lynch International at prices between 1,388.00p–1,412.50p, producing a VWAP of 1,397.84p. The shares will be held in treasury.
Since the non-discretionary mandate began on 4 Jun 2025, GSK has bought back 20,404,162 shares. Following the latest purchase the company now holds 238,538,545 treasury shares and has 4,076,849,940 ordinary shares in issue excluding treasury. Treasury shares account for 5.85 % of total voting rights, leaving 4,076,849,940 voting rights outstanding.
The filing provides trading-venue detail for compliance with FCA Disclosure Guidance & Transparency Rules and updates investors’ denominator for any shareholding notification requirements.
GSK plc has filed a Form 6-K to meet Financial Conduct Authority (FCA) Disclosure Guidance & Transparency Rule 5.6.1R. As of 31 July 2025 the company had 4,315,385,410 issued Ordinary Shares of 31 ¼ pence each. Of these, 237,044,421 shares were held in treasury, leaving 4,078,340,989 voting rights in circulation. Shareholders should use this denominator when calculating threshold notifications of holdings under FCA rules. The notice was authorised by Company Secretary V. A. Whyte and filed on 1 August 2025.
GSK plc filed a Form 6-K detailing a routine share repurchase executed on 31 July 2025 under its June-2025 non-discretionary buy-back mandate.
- Shares bought: 474,100 ordinary shares (nominal 31¼ p).
- Price range: 1,404.50–1,461.00 GBp; VWAP 1,423.11 GBp.
- Cumulative purchases since 4 June 2025: 18,910,038 shares.
The shares will be held in treasury, increasing the treasury balance to 237,044,421. Shares in issue (excluding treasury) now total 4,078,340,989, establishing the new denominator for voting-rights disclosures. Treasury stock represents 5.81 % of total voting rights.
No operational, earnings or guidance updates were provided; the filing primarily fulfils UK DTR 5.5.1R disclosure requirements.
Q2-25 snapshot: GSK generated turnover of £7.99 bn (+1% AER, +6% CER), led by Specialty Medicines (£3.33 bn, +15% CER) and Vaccines (£2.09 bn, +9% CER). Core operating profit rose 12% to £2.63 bn, lifting core margin 1.8 ppts to 32.9%; core EPS advanced 15% to 46.5 p. Total EPS climbed 35% on lower contingent-consideration charges. Cash generated from operations grew 47% to £2.43 bn, translating into £1.13 bn of free cash flow.
Guidance & capital returns: Management now expects FY-25 turnover, core operating profit and core EPS to reach the top end of prior 3-5%, 6-8% and 6-8% CER ranges. A 16 p dividend was declared (64 p FY target) and £822 m of a £2 bn buy-back executed in H1.
Pipeline momentum: Three FDA approvals received YTD (Penmenvy, Blujepa, Nucala-COPD); five major approvals targeted in 2025, with 14 late-stage assets each aiming for >£2 bn PYS. Phase III tebipenem stopped early for efficacy.
Key watch-points: General Medicines declined 6% CER, U.S. Shingrix demand softened and pricing pressure from U.S. IRA persisted. Core R&D spend increased 11% and included a £471 m impairment (belrestotug). Net debt edged to £13.7 bn after £0.8 bn acquisitions, £1.3 bn dividends and £0.8 bn buy-backs.